Cancer Drug Research and Pricing and More
In this week’s BioBlog we look at recent happenings in the development and research of cancer drugs, cancer drug price increases, a push by democrats for single-payer healthcare, new Alzheimer disease research, and the ongoing opioid prescription crisis in the US.
The Wall Street Journal reports that big pharma companies Novartis, Johnson & Johnson, and Sanofi are all working to develop drugs to treat the top three deadliest cancers in China.
Recently Merck announced that the FDA has placed three studies on the use of Keytruda in the treatment of Multiple Myeloma on hold. The move made due to more deaths in two of the studies.
Recently cancer drugs have continued to face price increases, added to the list recently were Blincyto and Treanda, increased by 3.9% and 4.5% respectively.
Recently more Democrats, including potential 2020 candidates, have been showing support toward a single-payer government run healthcare system, but they still lack support from key democratic leaders.
Recently researchers revealed for the first time the atomic structure of the tau protein filaments, a development that should help researchers in the development of new treatments for the disease.
This CDC report shows that while the prescribing of opioids in the US has slowed from its peak in 2010, the number still remains high and varies greatly by area.